Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + axitinib versus sunitinib for unresectable or metastatic renal cell carcinoma
CTR20200876Phase 3Completed
- Sponsor
- Junshi Biosciences
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab, axitinib, sunitinib in renal cell carcinoma (RCC), sponsored by Junshi Biosciences. Started Sep 2020; status: completed.
02
Drugs
toripalimabaxitinibsunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20200876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200876.